Kala Pharmaceuticals (KALA) Misses Q4 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St futures slide as rising oil, yields dampen mood
- Oil jumps as Middle East supply concerns persist amid shipping attacks
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
Tweet
Share
E-mailGet Alerts KALA Hot Sheet
Join SI Premium – FREE
Note: EPS may not be comparable
Kala Pharmaceuticals (NASDAQ: KALA) reported Q4 EPS of ($0.46), $0.09 worse than the analyst estimate of ($0.37).
For earnings history and earnings-related data on Kala Pharmaceuticals (KALA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
- Some Said Inflation Risks Had Become More Skewed To Upside - FOMC Minutes
- Neogen Corp. (NEOG) Tops Q1 EPS by 3c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
